Renal cell carcinoma (RCC) is the most common solid tumour of the kidney and accounts for 3% of all cancers. While immune checkpoint inhibitor (ICI)-based combination therapies have emerged as the first-line treatment for metastatic renal cell carcinoma (mRCC). the role of surgery has become more controversial. This review summarizes the evidence. https://www.jmannino.com/hot-price-Mules-Lupita-Trasparenti-hot-value/